{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:21:56Z","timestamp":1761060116724},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13256-016-0879-6","type":"journal-article","created":{"date-parts":[[2016,4,18]],"date-time":"2016-04-18T08:47:14Z","timestamp":1460969234000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report"],"prefix":"10.1186","volume":"10","author":[{"given":"Yen-Man","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsu-Ming","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chee-Yin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Nung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,18]]},"reference":[{"key":"879_CR1","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224\u201333.","journal-title":"Cancer."},{"key":"879_CR2","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","volume":"68","author":"M Roupr\u00eat","year":"2015","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol. 2015;68:868\u201379.","journal-title":"Eur Urol."},{"key":"879_CR3","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014;66:529\u201341.","journal-title":"Eur Urol."},{"key":"879_CR4","first-page":"1957","volume":"7","author":"NH Chow","year":"2001","unstructured":"Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res. 2001;7:1957\u201362.","journal-title":"Clin Cancer Res."},{"key":"879_CR5","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-06-0407","volume":"12","author":"KN Blehm","year":"2006","unstructured":"Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer. 2006;12:4671\u20137.","journal-title":"Clin Cancer."},{"key":"879_CR6","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1200\/JCO.2012.41.9572","volume":"30","author":"YN Wong","year":"2012","unstructured":"Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30:3545\u201351.","journal-title":"J Clin Oncol."},{"key":"879_CR7","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","volume":"366","author":"ND James","year":"2012","unstructured":"James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366:1477\u201388.","journal-title":"N Engl J Med."},{"key":"879_CR8","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/iju.12407","volume":"21","author":"TT Sio","year":"2014","unstructured":"Sio TT, Ko J, Gudena VK, Verma N, Chaudhary UB. Chemotherapeutic and targeted biological agents for metastatic bladder cancer: a comprehensive review. Int J Urol. 2014;21:630\u20137.","journal-title":"Int J Urol."},{"key":"879_CR9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","volume":"507","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507:315\u201322.","journal-title":"Nature"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-016-0879-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T07:11:53Z","timestamp":1498288313000},"score":1,"resource":{"primary":{"URL":"http:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-016-0879-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,18]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["879"],"URL":"https:\/\/doi.org\/10.1186\/s13256-016-0879-6","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,18]]},"article-number":"98"}}